Evidence map›Paper›PMID 35501800›Full record

ArticleCancer cell international2022

ZBTB7A, a miR-144-3p targeted gene, accelerates bladder cancer progression via downregulating HIC1 expression.

Junqiang Liu, Zhiyuan Chou, Chun Li, Kai Huang, Xuejian Wang, Xiunan Li, Chuanchun Han, Abdullah Al-Danakh, Xiaodong Li, Xishuang Song

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Junqiang Liu *Department of Urology of First Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Zhiyuan Chou *Department of Urology of First Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Chun Li *Central Laboratory, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
Kai HuangDepartment of Urology of First Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Xuejian WangDepartment of Urology of First Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Xiunan LiDepartment of Urology of First Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Chuanchun HanDepartment of Urology of First Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Abdullah Al-DanakhDepartment of Urology of First Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Xiaodong LiDepartment of Urology of First Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China. xd_li201212@dmu.edu.cn.
Xishuang SongDepartment of Urology of First Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China. song-xishuang@163.com.ORCID http://orcid.org/0000-0001-5720-3077
Dalian Medical University · CNAffiliated Zhongshan Hospital of Dalian University · CN

Funding

National Natural Science Foundation of China 11872146
6 · The paper itself

Abstract

backgroundZinc finger and BTB domain-containing 7A (ZBTB7A) is a member of the POK family of transcription factors that plays an oncogenic or tumor-suppressive role in different cancers depending on the type and genetic context of cancer. However, the function and molecular mechanism of ZBTB7A in bladder cancer (BC) remain elusive.

methodsThe role of ZBTB7A in bladder cancer was detected by colony formation, transwell, and tumor formation assays. The expression levels of ZBTB7A, HIC1, and miR-144-3p were analyzed by qRT-PCR and Western blot. Bioinformatics analysis and a dual-luciferase reporter assay were used to assess the effect of ZBTB7A on the promoter activity of HIC1.

resultsThe present study revealed that knockdown of ZBTB7A suppressed BC cell growth and migration, as indicated by an approximately 50% reduction in the number of colonies and an approximately 70% reduction in the number of migrated cells. Loss of ZBTB7A inhibited tumor growth in vivo, resulting in a 75% decrease in tumor volume and an 80% decrease in tumor weight. Further mechanistic studies revealed that ZBTB7A bound to the hypermethylated in cancer 1 (HIC1) promoter and downregulated HIC1 expression, accelerating the malignant behavior of BC. Increased expression of ZBTB7A in BC tissues was negatively corrected with the expression of HIC1. Moreover, ZBTB7A was a target of miR-144-3p, which decreased ZBTB7A expression in BC.

conclusionOur data demonstrate that ZBTB7A, a targeted gene of miR-144-3p, promoted tumorigenesis of BC through downregulating HIC1 expression.

Indexed as

Bladder cancerHIC1miR-144-3pZBTB7A

Identifiers

PMID35501800
PMCPMC9063087
OpenAlexW4225270307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.